)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Senzime
Senzime (SEZI) investor relations material
Senzime Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 net sales rose 14% reported and 12% currency-adjusted to SEK 30.099m; disposable sensor sales grew 43% across the US, Europe and Rest of World.
Gross margin reached 74.0%, EBITDA improved to SEK -8.026m and operating expenses fell 15% YoY.
Positive cash flow remains targeted within Q4 2026, though ambitious full-year sales growth targets remain challenging.
Financial highlights
Q1–Q3 sales were SEK 78.002m, up 3% reported and 7% currency-adjusted.
Q3 operating profit was SEK -14.232m vs SEK -25.425m; net loss was SEK 11.254m vs SEK 25.534m, with EPS of SEK -0.07 vs SEK -0.16.
Q3 cash flow improved to SEK -8.7m from SEK -28.3m; operating cash flow was SEK -6.3m vs SEK -23.8m.
Q1–Q3 EBITDA was SEK -45.495m vs SEK -63.806m; operating expenses were SEK 100.802m vs SEK 114.146m.
Q3 gross margin before depreciation on intangible assets was 74.0% vs 61.2%; excluding net US customs-duty effects, it was 73.2%.
Outlook and guidance
Positive cash flow remains targeted within Q4 2026, supported by sensor growth, improved margins, cost control and working-capital management.
Long-term gross margin ambition is above 70%; management cited challenges in meeting ambitious full-year sales growth targets.
Philips and other OEM partnerships are intended to become a second growth engine, with an ambition for OEM revenue to eventually exceed half of total revenue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Senzime
- Sensor sales up 48% and gross margin at 65.7%, with Q4 profitability on track.SEZI
Q2 2026 - Margins and cash flow improved, with strong sensor sales and major US contracts secured.SEZIQ1 2026
- Net sales grew over 90% and adjusted EBITDA improved 16%, with profitability targeted for 2026.SEZIQ4 2025
- Advanced nerve monitoring is revolutionizing anesthesia safety and driving rapid global growth.SEZILife Science Summit 2025
- 80% revenue growth, improved EBITDA, and major US contracts drive strong expansion.SEZIQ3 2025
- Q3 sales up 90% year-over-year, driven by sensor demand and US and Asia growth.SEZIQ3 2024
- Q2 sales up 76% year-over-year, driven by US growth and major new hospital contracts.SEZIQ2 2024
- Q1 2025 delivered 94% sales growth, margin gains, and major US and EU hospital wins.SEZIQ1 2025
- 2024 sales up 65%, next-gen TetraGraph launched, 2025 revenue set to double.SEZIQ4 2024
Next Senzime earnings date
Q4 202618 Feb, 2027
Senzime
Next Senzime earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Senzime AB is a medical technology company specializing in patient monitoring systems designed to enhance safety and efficiency in healthcare. The company develops and manufactures solutions for monitoring neuromuscular function and other critical physiological parameters during and after surgery. Senzime’s products aim to reduce complications, improve outcomes, and support personalized care in operating rooms and recovery units. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Nasdaq Stockholm Stock Exchange.